Ir al contenido

Información médica independiente para pacientes internacionales

Menú

Enfermedad

Breast cancer

CIE-10: C50 — Malignant neoplasm of breast

Grupo: Cáncer Especialidad: Cirugía de mama

Cifras clave

Solo valores publicados. Cada recuadro abre la sección que incluye su fuente, su año y su criterio.

Detalles de la enfermedad

Nombre en inglés
Malignant neoplasm of breast

También conocido como

  • Breast carcinoma

Intervalos de costos del tratamiento

Todos los intervalos de abajo se publican sobre una misma base de facturación: Antes del reembolso. Las fuentes no publican ninguna cifra posterior al reembolso, así que aquí no se muestra ninguna.

Ruta de tratamiento Intervalo de costos Base del precio Año de los datos
Cirugía 18000 – 28430 CNY Precio de paquete por enfermedad 2020–2025
Radioterapia 27000 – 45000 CNY Precio por ítem 2025–2026
Quimioterapia 6200 – 9000 CNY Precio de paquete por enfermedad 2020–2021
Terapia dirigida 100000 – 195000 CNY Precio por ítem 2025
Inmunoterapia 32043 – 42620 CNY Precio por ítem 2024–2025

Las barras comparten una sola escala en todas las filas de arriba: cada una empieza en la cifra publicada más baja de su fila y termina en la más alta. La cifra superior más alta de esta página es 195000 CNY. Cada fila conserva su propio año de datos y su criterio.

5 intervalos de costos para esta enfermedad, cada uno con su fuente en la página de la fila.

Los valores escritos en chino se citan tal como los publica la fuente.

Ver todos los intervalos de costos →

Supervivencia a cinco años

Tasa de supervivencia a 5 años 80.9% IC del 95% 80.5–81.3

Población
Global (todos los estadios combinados) · Supervivencia relativa estandarizada por edad
Período
2019–2021
Publicador
Centro Nacional del Cáncer de China
Naturaleza del valor
Valor estimado (análisis híbrido)
Alcance del registro
281 registros de cáncer de base poblacional
Disponibilidad de datos por estadio
No publicado

Los valores escritos en chino se citan tal como los publica la fuente.

Ver todas las tasas de supervivencia →

Cómo leer esta cifra. Se publica para todos los estadios combinados, así que es un promedio de todas las personas de los datos del registro nacional y no un pronóstico para una persona. En la mayoría de los cánceres, el estadio en el momento del diagnóstico es el factor único más determinante de las diferencias de supervivencia: la supervivencia suele ser mayor cuando el cáncer se detecta en un estadio más temprano y menor cuando se detecta más tarde. Las comparaciones entre cánceres también dependen de con qué antelación o retraso suele diagnosticarse cada uno, así que una cifra más baja no significa por sí sola peor atención.

La cifra es de supervivencia relativa: compara a las personas diagnosticadas de este cáncer con personas de la misma edad y sexo de la población general, y está estandarizada por edad, así que no es la proporción de pacientes que siguen vivos a los cinco años. Se publica como un valor estimado (análisis híbrido) porque los informes de los registros llegan con retraso, así que el Centro Nacional del Cáncer modeló el período más reciente. Como contexto, la misma fuente publica una supervivencia relativa a cinco años del 43,7% para todos los cánceres combinados en 2019–2021.

Hospitales con un registro publicado para esta enfermedad

Seleccionados con fuentes de datos públicas oficiales

Estos hospitales se seleccionan de fuentes de datos públicas oficiales —los rankings de reputación por especialidad de hospitales de la Universidad de Fudan, la lista de especialidades clínicas clave nacionales y los centros nacionales de investigación clínica—, de modo que cada línea de una tarjeta se puede contrastar con su fuente publicada. No es un listado pagado ni promocionado.

Cómo se seleccionaron estos hospitales

Inclusión. Un hospital se lista para una enfermedad cuando la especialidad en la que esta se clasifica cumple al menos una de estas condiciones: un puesto o una nominación en el ranking de reputación por especialidad de hospitales de la Universidad de Fudan; un registro de especialidad clínica clave nacional de nivel A, B o C; o un centro nacional de investigación clínica o un laboratorio estatal clave en esa especialidad. La acreditación JCI se muestra como distintivo; nunca decide la inclusión ni el orden.

Orden. Paso 1: un puesto de Fudan entre 1 y 10 en la especialidad. Paso 2: otro puesto de Fudan, o una nominación. Paso 3: una especialidad clínica clave nacional de nivel A. Paso 4: una especialidad clínica clave nacional de nivel B. Paso 5: un centro nacional de investigación clínica o un laboratorio estatal clave en la especialidad, primero el centro y luego el laboratorio. Paso 6: una especialidad clínica clave nacional de nivel C, que es un registro que publicamos sin una fuente oficial independiente y que por eso se lista después de los demás.

Empates. Dentro de un mismo paso: primero el puesto de Fudan más alto, luego el nivel de especialidad clave más fuerte (A antes que B antes que C), luego la provincia, luego la ciudad y luego el nombre del hospital, el mismo orden provincia-ciudad-nombre que usa el directorio de hospitales. Se listan como máximo ocho hospitales.

Cuando la lista es corta. Cinco hospitales o más: se listan los ocho primeros. Tres o cuatro: se listan todos y un pliegue adicional añade los registros restantes hasta ocho, cada uno con su nivel de evidencia. Uno o dos: lo mismo, con ese pliegue abierto y una línea que indica cuántos hospitales tienen un historial público sólido. Ninguno: la página declara que no se encontró ningún historial público sólido y enlaza al directorio de especialidades. Nunca se inventa un puesto, una institución ni un recuento para rellenar la lista.

Los rankings de Fudan son el ranking de reputación por especialidad de hospitales más ampliamente reconocido por los clínicos chinos, publicado cada año por el instituto de gestión hospitalaria de la Universidad de Fudan.

  1. West China Hospital, Sichuan University

    Chengdu

    Especialidad clínica clave nacional

    También en el ranking: Cirugía general #3, Cirugía torácica #4, Urología #2 (empatado) en la lista de Fudan.

  2. Qilu Hospital of Shandong University

    Jinan

    Especialidad clínica clave nacional

    Investigación publicada

    3 estudios publicados más

    PubMed indexa 5 artículos sobre esta enfermedad que mencionan este hospital.

    También en el ranking: Ginecología #7 (empatado), Otorrinolaringología nominado, Gastroenterología nominado en la lista de Fudan.

  3. Shandong Cancer Hospital

    Jinan

    Especialidad clínica clave nacional

  4. Hubei Cancer Hospital

    Wuhan

    Especialidad clínica clave nacional

    Investigación publicada

    3 estudios publicados más

    PubMed indexa 5 artículos sobre esta enfermedad que mencionan este hospital.

  5. Hunan Cancer Hospital

    Changsha

    Especialidad clínica clave nacional

    Investigación publicada

    PubMed indexa 1 artículo sobre esta enfermedad que menciona este hospital.

    También en el ranking: Oncología médica nominado en la lista de Fudan.

Ensayos clínicos (tratamientos en investigación)

Además de la atención estándar, es posible que actualmente haya estudios de investigación clínica para Breast cancer abiertos a participantes en China. Los tratamientos en estudio no han sido aprobados por el regulador como terapia estándar: son investigación clínica, no tratamiento de rutina. Cada registro indica el investigador principal y el hospital que realiza el estudio. Si te interesa, contacta con el hospital para preguntar por los criterios de elegibilidad y decide si solicitas participar.

  1. Estudio To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients: A Prospective, Multicenter, Non-interventionist Real World Study

    Hospital
    Henan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06605521

  2. Estudio Integrated PET/MRI Study of Cognitive Impairment in Premenopausal Breast Cancer Patients After Chemotherapy or Endocrine Therapy

    Estado
    En reclutamiento
    Registro
    NCT05305092

  3. Estudio The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery: an Observational Cohort Study

    Investigador principal
    Chen Kai · Clinical Professor
    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Estado
    En reclutamiento
    Registro
    NCT06425874

  4. Estudio Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

    Hospital
    Tianjin Medical University Cancer Institute & Hospital
    Estado
    En reclutamiento
    Registro
    NCT07372079

  5. Estudio Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer

    Hospital
    The Affiliated Hospital of Qingdao University
    Estado
    En reclutamiento
    Registro
    NCT06916338
126 estudios registrados más

  1. Estudio Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Stage II-III HER2-positive Breast Cancer Patients Who Have Poor Outcomes After Treatment With Trastuzumab and Pertuzumab

    Investigador principal
    Caigang Liu · Director
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT04983121

  2. Estudio Effect of Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer Without Lymph Node Metastasis Instead of Conventional Imaging Examination After Operation: a Non-Inferiority Randomized Controlled Clinical Trial

    Investigador principal
    Jianyi Li · Principal Investigator
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT04065321

  3. Estudio A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

    Investigador principal
    Caigang Liu · Director of the Cancer Center
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT05635487

  4. Estudio VERITAS Longitudinal Real-world Registry of HR+/HER2- mBC to Understand Treatment Pattern and Clinical Outcomes in HR+/HER2- mBC

    Hospital
    Jiangsu Province Hospital
    Estado
    En reclutamiento
    Registro
    NCT07743944

  5. Estudio A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.

    Hospital
    Anhui Provincial Hospital
    Estado
    En reclutamiento
    Registro
    NCT05872347

  6. Estudio Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in All-Scenario Breast Cancer Radiotherapy: A Prospective Clinical Study

    Investigador principal
    Xiaoli Yu · Professor
    Hospital
    Fudan University Shanghai Cancer Center
    Estado
    En reclutamiento
    Registro
    NCT07776301

  7. Estudio A Cohort Study of Adjuvant Therapy With Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

    Investigador principal
    Shu Wang · director of breast center
    Hospital
    Peking University People's Hospital
    Estado
    En reclutamiento
    Registro
    NCT06711055

  8. Estudio Neoadjuvant Therapy Study Guided by Drug Screening in Vitro Patient-derived Tumor-like Cell Clusters for HER2 Positive Early Breast Cancer Patients

    Hospital
    Peking University People's Hospital
    Estado
    En reclutamiento
    Registro
    NCT04750122

  9. Estudio Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial

    Estado
    En reclutamiento
    Registro
    NCT06938360

  10. Estudio A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    Investigador principal
    Shuangyue Liu · Clinical Professor
    Hospital
    West China Hospital, Sichuan University
    Estado
    En reclutamiento
    Registro
    NCT05447702

  11. Estudio Application of Radiomics in Correlation Between Ultrasound Characteristics and Pathological Prognostic Factors in Breast Cancer

    Hospital
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Estado
    En reclutamiento
    Registro
    NCT04483804

  12. Estudio Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

    Hospital
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Estado
    En reclutamiento
    Registro
    NCT07616440

  13. Estudio Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05): A Prospective, Single-arm, Multi-center Clinical Study

    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Estado
    En reclutamiento
    Registro
    NCT06832904

  14. Estudio Safety and Feasibility of Irreversible Electroporation for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study

    Investigador principal
    Tian'an Jiang · Chief Physician
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Estado
    En reclutamiento
    Registro
    NCT07263451

  15. Estudio Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) for Chronic Insomnia in Breast Cancer Survivors, A Randomized Controlled Trial

    Investigador principal
    Jing MA · Pro.
    Hospital
    Peking University First Hospital
    Estado
    En reclutamiento
    Registro
    NCT05813392

  16. Estudio Impact of Erector Spinae Plane Block With Adjuvant Dexmedetomidine on Chronic Postsurgical Pain in Breast Cancer Patients: a Two-center Randomized Controlled Trial

    Investigador principal
    Dong-Xin Wang · Professor
    Hospital
    Peking University First Hospital
    Estado
    En reclutamiento
    Registro
    NCT05494502

  17. Estudio A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT05851014

  18. Estudio A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT07673029

  19. Estudio A Real-World Observational Study on Post-Resistance Treatment Outcomes in Advanced Breast Cancer Patients After CDK4/6 Inhibitors, PIK3CA Inhibitors, or Trastuzumab Deruxtecan Therapy

    Hospital
    Hunan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT07073755

  20. Estudio A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6is.

    Hospital
    Hunan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06734533

  21. Estudio A Prospective, Multigroup, Multi-center, Open-label Clinical Study of Trastuzumab Rezetecan as Neoadjuvant Therapy Combined With Toripalimab in HR+/HER2-low Breast Cancer Patients (NEOTORCH-BREAST 08)

    Hospital
    Third Affiliated Hospital of Harbin Medical University
    Estado
    En reclutamiento
    Registro
    NCT07383818

  22. Estudio A Randomized, Multi-center, Open-label, Phase III Trial of Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer (FAMILY)

    Investigador principal
    Herui Yao · Principal Investigator
    Hospital
    Guangdong Provincial People's Hospital
    Estado
    En reclutamiento
    Registro
    NCT04263298

  23. Estudio A Randomized, Open-label, Multicenter Study Comparing Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

    Hospital
    Fujian Medical University Union Hospital
    Estado
    En reclutamiento
    Registro
    NCT05292742

  24. Estudio Trastuzumab Combined With Pyrotinib and Chemotherapy for Locally Advanced, Inflammatory, or Early HER2-positive Mammary glandsCancer: One Arm, Open, Phase II Clinical Study

    Investigador principal
    Tao OUYANG · Chairman of Breast Center of Peking University Cancer Hospital
    Hospital
    Peking University Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT04481932

  25. Estudio Intraoperative Nomogram to Predict Breast Cancer- Related Lymphedema Based in Artificial Intelligence Image Recognition: a Randomized Controlled Trial

    Investigador principal
    Gaosong Wu, Ph D, MD · Director
    Hospital
    Zhongnan Hospital of Wuhan University
    Estado
    En reclutamiento
    Registro
    NCT04665882

  26. Estudio A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Hospital
    Peking University Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06120283

  27. Estudio A Randomized Controlled, Open-label, Multicenter Clinical Study of Pyrotinib Maleate Combined With Trastuzumab,Dalpiciclib, and Letrozole Versus Trastuzumab Combined With Pertuzumab, Docetaxel, and Carboplatin as Neoadjuvant Therapy for Stage II-III HR +/HER2 + Breast Cancer

    Investigador principal
    Caigang Liu · Professor
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT05638594

  28. Estudio Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer

    Investigador principal
    Jianyi Li · Principal Investigator
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT05346510

  29. Estudio A Phase II, Multicenter, Open-Label Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination With Pertuzumab With or Without Toripalimab for HER2 Positive Breast Cancer

    Hospital
    Fudan University Shanghai Cancer Center
    Estado
    En reclutamiento
    Registro
    NCT06178159

  30. Estudio Effect of Neoadjuvant Radiation and Prediction of Response to Treatment in Locally Advanced Breast Cancer

    Investigador principal
    Xiaoli Yu · Professor
    Hospital
    Fudan University Shanghai Cancer Center
    Estado
    En reclutamiento
    Registro
    NCT05479409

  31. Estudio A Cohort Study of Different Choice of Adjuvant Therapy in Non-PCR Patients With HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

    Investigador principal
    Shu Wang · director of breast center
    Hospital
    Peking University People's Hospital
    Estado
    En reclutamiento
    Registro
    NCT06693037

  32. Estudio A Single-center, Single-arm, Open Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery

    Estado
    En reclutamiento
    Registro
    NCT07071402

  33. Estudio Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer

    Estado
    En reclutamiento
    Registro
    NCT07012720

  34. Estudio A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

    Hospital
    Beijing Hospital
    Estado
    En reclutamiento
    Registro
    NCT05950945

  35. Estudio Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression

    Hospital
    Xiangya Hospital of Central South University
    Estado
    En reclutamiento
    Registro
    NCT06938373

  36. Estudio A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribulin Versus Physician's Choice Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

    Investigador principal
    Jieqiong Liu, M.D., Ph.D. · Professor
    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Estado
    En reclutamiento
    Registro
    NCT06889688

  37. Estudio Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer (TAYLOR-003)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT07616427

  38. Estudio A Randomized, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in Patients With HER2-positive Advanced Breast Cancer

    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Estado
    En reclutamiento
    Registro
    NCT07008976

  39. Estudio Monitoring Circulating Tumor DNA in Patients With Early Stage Breast Cancer

    Estado
    En reclutamiento
    Registro
    NCT04353557

  40. Estudio A Prospective, Randomized Controlled Phase II Trial Investigating the Optimal Timing of Antibody Drug Conjugates in Advanced HER2-Negative Breast Cancer Patients

    Investigador principal
    Tao Sun · Principal Investigator
    Hospital
    Liaoning Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT07657130

  41. Estudio A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Ivonescimab Neoadjuvant Therapy for Luminal-type Breast Cancer

    Investigador principal
    HAN GUANG · professor
    Hospital
    Hubei Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06402435

  42. Estudio A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Cadonilimab (AK104) Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

    Investigador principal
    HAN GUANG · professor
    Hospital
    Hubei Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06401005

  43. Estudio Gut Microbiota Changes in Breast Cancer Patients Treated With Pyrotinib and Correlation With Drug-Induced Diarrhea: An Observational Cohort Study

    Investigador principal
    Xinhong Wu, PhD · vice-president
    Hospital
    Hubei Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT07264985

  44. Estudio Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold for Left Sided Breast Cancer, A Real-World Study

    Hospital
    Peking Union Medical College Hospital
    Estado
    En reclutamiento
    Registro
    NCT06660628

  45. Estudio Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

    Hospital
    Peking Union Medical College Hospital
    Estado
    En reclutamiento
    Registro
    NCT06411678

  46. Estudio A Single-center, Blinded, Efficacious, Phase III Randomized Clinical Trial Initiated by Investigators to Investigate the Use of Surface Guided Radiation Therapy (SGRT) in Combination With Deep Inspiration Breath Hold (DIBH) Technique for Left Breast Cancer Treatment, Compared to Traditional Laser Alignment With Free Breathing Treatment

    Hospital
    Peking Union Medical College Hospital
    Estado
    En reclutamiento
    Registro
    NCT05804916

  47. Estudio Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study

    Investigador principal
    Zhimin Shao · Professor
    Hospital
    The First Affiliated Hospital of Anhui Medical University
    Estado
    En reclutamiento
    Registro
    NCT04790305

  48. Estudio Surveillance of Circulating Tumor Cell Phenotype in Early Stage Breast Cancer Patients With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy

    Hospital
    Hunan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT05326295

  49. Estudio A Single-arm, Multicenter, Open-labeled Clinical Study of UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

    Hospital
    Hunan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT05535413

  50. Estudio A Clinical Study of Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR Positive HER2 Positive Breast Cancer

    Hospital
    Henan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06276868

  51. Estudio Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer: a Prospective, Multicenter, Single Arm, Real World Study

    Hospital
    Henan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06518135

  52. Estudio A Single-arm, Prospective, Open-label Phase II Clinical Study of Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

    Hospital
    Henan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT05398861

  53. Estudio Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

    Investigador principal
    Zhenzhen Liu · Professor
    Hospital
    Henan Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06860529

  54. Estudio Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With HER2 Negative Metastatic Breast Cancer Treated With Sacituzumab Govitecan: A Retrospective Trial in China（SACIT-OUT）

    Investigador principal
    Wang Xiaojia · MD
    Hospital
    Zhejiang Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06784921

  55. Estudio A Phase II, Randomised, Open-label, Multicentre Study of Posaconazole Plus PD-1 Inhibitors and Chemotherapy Versus PD-1 Inhibitors and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer

    Investigador principal
    Yongsheng Wang · Professor
    Hospital
    Shandong Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT06802757

  56. Estudio Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

    Hospital
    Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
    Estado
    En reclutamiento
    Registro
    NCT06977893

  57. Estudio A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

    Hospital
    China-Japan Friendship Hospital
    Estado
    En reclutamiento
    Registro
    NCT06210776

  58. Estudio Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating

    Investigador principal
    Yong Yang · Chief physician
    Hospital
    Fujian Medical University Union Hospital
    Estado
    En reclutamiento
    Registro
    NCT05704166

  59. Estudio Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy: a Phase III Randomized, Controlled Clinical Trial

    Investigador principal
    Yong Yang · M.D.
    Hospital
    Fujian Medical University Union Hospital
    Estado
    En reclutamiento
    Registro
    NCT06559696

  60. Estudio A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Evaluating TQB2930 Combined With Investigator's Choice of Chemotherapy Versus Trastuzumab Combined With Investigator's Choice of Chemotherapy in the Treatment of HER2-Positive Advanced Breast Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT07047365

  61. Estudio Efficacy and Safety of Probiotics Versus Standard Care in Preventing Diarrhea Induced by Neratinib in Breast Cancer Patients: A Prospective Randomized Controlled Clinical Trial

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Estado
    En reclutamiento
    Registro
    NCT06892093

  62. Estudio Disitamab Vedotin in Combination With Pyrotinib Versus THP in the First-line Treatment for HER2-positive Advanced Breast Cancer, a Multicentre, Randomized, Double-blind Controlled, Phase III Trial

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Estado
    En reclutamiento
    Registro
    NCT06278870

  63. Estudio Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

    Hospital
    The Affiliated Hospital of Qingdao University
    Estado
    En reclutamiento
    Registro
    NCT06916637

  64. Estudio A Non-interventional Study to Evaluate the Effectiveness and Safety of Inavolisib in Patients With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (reaINAVO)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT07347600

  65. Estudio An Interventional, Multicenter Study of Trastuzumab Rezetecan as Neoadjuvant Therapy in Patients With THP-Insensitive HER2-Positive Early Breast Cancer

    Investigador principal
    Hao Zhou · Associate Chief Physician
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT07647263

  66. Estudio Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial

    Investigador principal
    Caigang Liu · Principal Investigator
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT04137653

  67. Estudio The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer

    Investigador principal
    Caigang Liu · Director of oncology
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT06690645

  68. Estudio The Efficiency for Patient With Stage II-III HR+/HER2+ Early Breast Cancer With Standard Neoadjuvant Therapy: a Retrospective, Multicenter Study in Real World Settings.

    Investigador principal
    Caigang Liu · Professor
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT05263570

  69. Estudio Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial

    Investigador principal
    Caigang Liu · Principal Investigator
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT04136782

  70. Estudio The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer

    Investigador principal
    Caigang Liu · director of oncology
    Hospital
    Shengjing Hospital
    Estado
    En reclutamiento
    Registro
    NCT06698679

  71. Estudio A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT06827236

  72. Estudio A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TT-00420 (Tinengotinib) Tablets Combined With Fulvestrant Injection in Patients With Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER-2) Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

    Hospital
    Guangdong Provincial People's Hospital
    Estado
    En reclutamiento
    Registro
    NCT07498478

  73. Estudio Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial

    Investigador principal
    Zhong-yu Yuan · Clinical Professor
    Hospital
    Sun Yat-sen University Cancer Center
    Estado
    En reclutamiento
    Registro
    NCT04722978

  74. Estudio A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer: A Prospective Randomized Controlled Trial

    Investigador principal
    Kun Wang · Clinical Professor
    Hospital
    Guangdong Provincial People's Hospital
    Estado
    En reclutamiento
    Registro
    NCT07352930

  75. Estudio A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients

    Investigador principal
    Kun Wang · Professor
    Hospital
    Guangdong Provincial People's Hospital
    Estado
    En reclutamiento
    Registro
    NCT06811870

  76. Estudio Clinical Cohort Study of 21-gene Assay in Predicting the Prognosis of Elder Luminal-A Breast Cancer Patients With Axillary Lymph Node Metastasis

    Hospital
    Qilu Hospital of Shandong University
    Estado
    En reclutamiento
    Registro
    NCT06891651

  77. Estudio Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined With TROP2 ADC in the Treatment of Brain Metastases in Triple-negative Breast Cancer

    Investigador principal
    Jian Zhang,MD · Director of Phase I clinical Research ward
    Hospital
    Fudan University Shanghai Cancer Center
    Estado
    En reclutamiento
    Registro
    NCT06793332

  78. Estudio Evaluating Safety and Efficacy of INtrathecal or Ommaya ReserVoir Administration of T-DXd in Patients With HER2-Expressing Breast Cancer With Active Leptomeningeal and/or Brain Metastases Based on Systemic Therapy: Phase I/II Study

    Investigador principal
    Jian Zhang,MD · Director of Phase I Clinical Trial Department; Professor, Chief physician of oncology department
    Hospital
    Fudan University Shanghai Cancer Center
    Estado
    En reclutamiento
    Registro
    NCT07134153

  79. Estudio A Prospective, Randomized, Open-label Phase III Clinical Study of the Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy Versus Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

    Investigador principal
    Zhimin Shao · Chief Physician
    Hospital
    Peking University Cancer Hospital
    Estado
    En reclutamiento
    Registro
    NCT05891093

  80. Estudio Cohort Study of Adjuvant Chemotherapy Combined With Targeted Therapy for Intermediate Risk HER2 Positive and Lymph Node Negative Early Breast Cancer

    Investigador principal
    Shu Wang · director of breast center
    Hospital
    Peking University People's Hospital
    Estado
    En reclutamiento
    Registro
    NCT06711068

  81. Estudio A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy

    Hospital
    Cancer Hospital of Chinese Academy of Medical Sciences
    Estado
    En reclutamiento
    Registro
    NCT07679360

  82. Estudio IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

    Hospital
    Anhui Provincial Hospital
    Estado
    En reclutamiento
    Registro
    NCT06926868

  83. Estudio A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT06891833

  84. Estudio A Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Estado
    En reclutamiento
    Registro
    NCT07043725

  85. Estudio The Safety and Efficacy of IMPT or IMRT for Breast Cancer: A Prospective Observational Study

    Investigador principal
    JIAYI CHEN · Chair of Radiation Oncology Department
    Hospital
    Ruijin Hospital
    Estado
    En reclutamiento
    Registro
    NCT06826885

  86. Estudio Prospective Randomized Controlled Study on Precision Irradiation of Regional Lymph Node for Clinical High-risk pN0 Breast Cancer

    Investigador principal
    JIAYI CHEN · Prof
    Hospital
    Ruijin Hospital
    Estado
    En reclutamiento
    Registro
    NCT05976412

  87. Estudio Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy: a Prospective, Multicenter, Clinical Trial

    Investigador principal
    Chunyan Ma · Chief of Cardiovascular Ultrasound
    Hospital
    First Hospital of China Medical University
    Estado
    En reclutamiento
    Registro
    NCT06282796

  88. Estudio A Phase 2 Trial of SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

    Investigador principal
    Min Yan, MD · Chief physician
    Hospital
    Henan Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07125950

  89. Estudio Sensitivity and Specificity of Ultrasound-Guided Core Needle Biopsy in Evaluating Axillary Lymph Node Metastasis in Breast Cancer

    Investigador principal
    Dezhi Zhang · Principal Investigator (PI)
    Hospital
    The First Hospital of Jilin University
    Estado
    Aún sin reclutar
    Registro
    NCT07573657

  90. Estudio A Multicenter, Randomized, Controlled, Open Label Clinical Study on the Treatment of Recurrent or Metastatic Triple Negative Breast Cancer With Cadonilimab Combined With Eribulin Versus Eribulin Alone

    Investigador principal
    Caigang Liu · Postdoctoral, Chief Physician
    Hospital
    Shengjing Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT06202313

  91. Estudio An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

    Investigador principal
    Caigang Liu · Shengjing Hospital
    Hospital
    Shengjing Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07101614

  92. Estudio A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients

    Investigador principal
    Kun Wang · PhD
    Hospital
    Guangdong Provincial People's Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT06825975

  93. Estudio A Phase 2, Single Arm Study Investigating the Use of Chidamide and PD-1 Antibody Combination With Anlotinib in HER2-low, Unresectable and/or Metastatic Breast Cancer

    Investigador principal
    Kun Wang · Professor
    Hospital
    Guangdong Provincial People's Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT06547476

  94. Estudio Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer After Trastuzumab Deruxtecan Resistance:A Single-Arm, Multicenter, Exploratory Clinical Study

    Estado
    Aún sin reclutar
    Registro
    NCT07333937

  95. Estudio Tolerability of Dalpiciclib Versus Abemaciclib/Ribociclib in Combination With Standard Endocrine Therapy for HR-Positive/HER2-Negative Early Breast Cancer: A Prospective, Multicenter, Randomized Controlled Trial

    Investigador principal
    Zhenzhen Liu · Professor
    Hospital
    Henan Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07706933

  96. Estudio A Multicenter, Prospective, Randomized Two-arm Controlled Trial Comparing the Impact of Robotic Versus Endoscopic Surgery on Breast Nerve Function Following Nipple-sparing Mastectomy for Breast Cancer

    Investigador principal
    haiyanli · Chief Physician, Department of Breast Surgery
    Hospital
    Guangzhou Women and Children's Medical Center
    Estado
    Aún sin reclutar
    Registro
    NCT07850154

  97. Estudio Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

    Hospital
    The First Hospital of Jilin University
    Estado
    Aún sin reclutar
    Registro
    NCT06868017

  98. Estudio Efficacy and Safety of SHR-A1811 Versus Pyrotinib Plus Capecitabine in Patients With Trastuzumab Primary-Resistant HER2-Positive Advanced Breast Cancer：A Prospective, Multicenter, Open-Label, Randomized, Controlled Study

    Investigador principal
    Hanfang Jiang, MD · Professor
    Hospital
    Peking University Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07417241

  99. Estudio A Clinical Model Based on Dynamic Changes in Anti-Müllerian Hormone to Predict Ovarian Reserve in Perimenopausal Breast Cancer Patients

    Investigador principal
    Jianyi Li · Chief Physician
    Hospital
    Shengjing Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07497191

  100. Estudio Trastuzumab Combined With Pertuzumab and Sequential Use of Pyrotinib vs. Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

    Investigador principal
    Caigang Liu · Director
    Hospital
    Shengjing Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT04973319

  101. Estudio Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer

    Investigador principal
    Kun Wang · Professor
    Hospital
    Guangdong Provincial People's Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07077018

  102. Estudio A Prospective Study to Evaluate the Clinical Significance of Medical Humanities-based Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage

    Investigador principal
    Jiong Wu · Principal Investigator
    Hospital
    Fudan University Shanghai Cancer Center
    Estado
    Aún sin reclutar
    Registro
    NCT06965556

  103. Estudio 针刺治疗激素受体阳性乳腺癌患者潮热的随机对照试验研究，A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer

    Investigador principal
    Shu Wang · director of breast center
    Hospital
    Peking University People's Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07294339

  104. Estudio A Multicenter, Single-Arm, Open-Label Study of Extended Sentinel Lymph Node Biopsy Using Methylene Blue as a Single Tracer After Neoadjuvant Therapy in Patients With Axillary Node-Positive Breast Cancer

    Estado
    Aún sin reclutar
    Registro
    NCT07532096

  105. Estudio SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Estado
    Aún sin reclutar
    Registro
    NCT06975475

  106. Estudio Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression: A Randomized Controlled Trial

    Investigador principal
    Weidong Mi · Director (Cheif expert of National key research and development program of China 2018YFC2001900)
    Hospital
    Chinese PLA General Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07374198

  107. Estudio Effects of Acupuncture for Anxiety and/or Depression Among Patients With Breast Cancer

    Investigador principal
    Yuanjie Sun · Attending physician
    Hospital
    Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    Estado
    Aún sin reclutar
    Registro
    NCT07183813

  108. Estudio Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer: A Historical Cohort Study

    Hospital
    Zhejiang Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07188116

  109. Estudio A Prospective Clinical Study Evaluating Bemotuzumab Combined With Chemotherapy to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

    Investigador principal
    Xuli Meng · Chief physician
    Hospital
    Zhejiang Provincial People's Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT06975644

  110. Estudio A Phase Ib, Open-label, Modular Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

    Hospital
    Hunan Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07163481

  111. Estudio The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

    Investigador principal
    Wang Xiaojia · chief physician
    Hospital
    Zhejiang Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT06140576

  112. Estudio A Prospective and Multicenter Clinical Study to Identify the Molecular Characterization and Subtypes in Patients With HER2-positive Breast Cancer Receiving Neoadjuvant Trastuzumab and Pertuzumab.

    Investigador principal
    Jinming Yu · PhD, MD
    Hospital
    Shandong Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07187752

  113. Estudio Efficacy and Safety of Pedicled Lateral Chest Wall Lymph-Adipofascial Flap Axillary Reconstruction for the Prevention of Breast Cancer-Related Arm Lymphedema: A Prospective, Single-Arm, Phase II Clinical Study

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Estado
    Aún sin reclutar
    Registro
    NCT07415200

  114. Estudio A Multicenter, Prospective Phase II Single-arm Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with T-DXd in Combination with an Immune Checkpoint Inhibitor in HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

    Investigador principal
    Huijin Wang · Director of Thyroid and Breast Disease Center
    Hospital
    Guangzhou Women and Children's Medical Center
    Estado
    Aún sin reclutar
    Registro
    NCT06733233

  115. Estudio Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3126 in Subjects With Breast Cancer

    Hospital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Estado
    Aún sin reclutar
    Registro
    NCT07697443

  116. Estudio A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases, With or Without Leptomeningeal Metastases.

    Hospital
    Peking University Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07177950

  117. Estudio A Prospective, Double-Arm Study on the Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

    Investigador principal
    xuliang · professor
    Hospital
    Peking University Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07527806

  118. Estudio Prospective Evaluation of Sentinel Lymph Node Biopsy Combined With Wire Localized Lymph Node Biopsy for Omitting Axillary Lymph Node Dissection in Breast Cancer Patients With 1-2 Sonographically Abnormal Lymph Nodes: A Diagnostic Study

    Hospital
    Peking University Cancer Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07791771

  119. Estudio Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes (HS-IT101) for the Treatment of Advanced Breast Cancer

    Hospital
    The Affiliated Hospital of Qingdao University
    Estado
    Aún sin reclutar
    Registro
    NCT05505812

  120. Estudio A Single-Center Retrospective Study to Develop a Nomogram for Predicting Recurrence in HR+/HER2- Early Breast Cancer Using Real-World Data

    Investigador principal
    Jianyi Li · Principal Investigator
    Hospital
    Shengjing Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07484763

  121. Estudio An Exploration of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery

    Investigador principal
    Kun Wang · Professor
    Hospital
    Guangdong Provincial People's Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT06811857

  122. Estudio A Multicenter, Randomized, Open-Label, Controlled Phase II Clinical Study of Paclitaxel Polymeric Micelles Combined With Trastuzumab and Pertuzumab (HP) and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer

    Investigador principal
    Jian Zhang,MD · Director of Phase I Unit，Chief physician of oncology department
    Hospital
    Fudan University Shanghai Cancer Center
    Estado
    Aún sin reclutar
    Registro
    NCT07581795

  123. Estudio A Multicenter, Prospective, Randomized Phase II Trial Evaluating Trastuzumab, Pertuzumab, Docetaxel Combined With QL1706 Versus Combined With Carboplatin as Neoadjuvant Therapy for Early or Locally Advanced HER2+ Breast Cancer

    Hospital
    Guangdong Provincial People's Hospital
    Estado
    Aún sin reclutar
    Registro
    NCT07246317

  124. Estudio Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

    Investigador principal
    Yingying Xu · Professor
    Hospital
    First Hospital of China Medical University
    Estado
    Aún sin reclutar
    Registro
    NCT07305246

  125. Estudio TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

    Investigador principal
    Yingying Xu · Professor
    Hospital
    First Hospital of China Medical University
    Estado
    Aún sin reclutar
    Registro
    NCT07271992

  126. Estudio Effect of Intraoperative Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery: A Multicenter, Randomized, Double-Blind, Sham-Controlled Trial

    Investigador principal
    Weidong Mi · Director (Cheif expert of National key research and development program of China 2018YFC2001900)
    Hospital
    Beijing Tiantan Hospital, Capital Medical University
    Estado
    Aún sin reclutar
    Registro
    NCT07458646

Esta página solo comparte información de estudios registrados públicamente. No recomienda ni anima a participar en ningún estudio. La participación es totalmente voluntaria y los riesgos de un tratamiento no aprobado son desconocidos; contacta directamente con el hospital para conocer los criterios de elegibilidad y los detalles del consentimiento informado.

Terapias avanzadas: qué está autorizado y qué está en ensayos

Hospitales con un registro de especialidad clave nacional

Mostrar los registros de hospitales 5 hospitales con un registro de especialidad clave

Cada fila es un hospital con un registro de especialidad clínica clave nacional en una especialidad en la que se clasifica esta enfermedad. Es un registro de listados publicados, no una recomendación ni un ranking.

Hospital Ciudad Especialidad (tal como se publicó) Evidencia Fuente
West China Hospital, Sichuan University
Tier 3 · MÁS ALTO
 Chengdu Cirugía de mama Nivel A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Qilu Hospital of Shandong University
Tier 3 · MÁS ALTO
 Jinan Cirugía de mama Nivel A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Shandong Cancer Hospital Jinan Cirugía de mama Nivel A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Hubei Cancer Hospital Wuhan Cirugía de mama Nivel B https://www.hbch.com.cn/category/1-11.html
Hunan Cancer Hospital
Tier 3 · MÁS ALTO
 Changsha Cirugía de mama Nivel B https://hnca.org.cn/wap/zdks/

5 hospitales con un registro de especialidad clave nacional que coincide.

Los valores escritos en chino se citan tal como los publica la fuente.

Lo que reportan los pacientes

Solo cifras agregadas: un resultado nacional citado con su fuente y el año al que se refiere. No es el testimonio de un paciente ni una afirmación sobre una sola persona.

  • Según lo publicado en National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023): National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.

    National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).

    Fuente: National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Nivel A

Todos los temas de terapias y acceso

Preguntas sobre esta enfermedad

No podemos dar asesoramiento médico, pero sí responder preguntas sobre esta página y sobre cómo organizar un tratamiento en China.

Consúltenos sobre esta enfermedad

Códigos CIE

Mostrar la tabla de códigos 10 códigos CIE
Versión Código Nombre en esa versión
ICD-10-WHO C50 Malignant neoplasm of breast
ICD-10-WHO C50.0 Nipple and areola
ICD-10-WHO C50.1 Central portion of breast
ICD-10-WHO C50.2 Upper-inner quadrant of breast
ICD-10-WHO C50.3 Lower-inner quadrant of breast
ICD-10-WHO C50.4 Upper-outer quadrant of breast
ICD-10-WHO C50.5 Lower-outer quadrant of breast
ICD-10-WHO C50.6 Axillary tail of breast
ICD-10-WHO C50.8 Overlapping lesion of breast
ICD-10-WHO C50.9 Breast, unspecified

Las filas son las entradas CIE-10 de la OMS para esta enfermedad, citadas tal como se publicaron.

Fuente y evidencia

URL de la fuente
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Esquema de la fuente
https
Tipo de fuente
Comisión de salud provincial
Nivel de evidencia
A - declarado por una comisión de salud, un instituto nacional de investigación o una universidad
Recuperado el
2026-09-24